Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

H. Lundbeck commences phase II trials for Lu-AE-58054

Nov. 28, 2008

Recent AstraZeneca and Abbott patents report novel analgesic agents

Nov. 28, 2008

Severity reduction of EAE with new sPLA2 inhibitor peptide

Nov. 27, 2008

Preladenant meets primary endpoint in phase II dose-finding trial in PD

Nov. 27, 2008

Schering-Plough reports top-line results for Saphris in schizophrenia

Nov. 27, 2008

FDA extends review of Somaxon's NDA for insomnia drug Silenor by 3 months

Nov. 27, 2008

FDA accepts for review Labopharm's trazodone NDA for major depressive disorder

Nov. 27, 2008

Sangamo's new zinc finger protein transcription factor neuroprotective in spinal injury model

Nov. 27, 2008

Antiallodynic activity of Adolor's novel potent NGF-TrkA antagonist

Nov. 26, 2008

UWA-0121 extends L-DOPA activity in primate model of Parkinson's disease

Nov. 26, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 1, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
CINP 2026: Gut microbiota could predict antidepressant response
BioWorld
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...
Ascending BCI systems deepen national security, ethical concerns
BioWorld
Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...